0
Nov 10 (Reuters) – Johnson & Johnson said on Tuesday its drug Caplyta eased manic symptoms better than placebo in a second late-stage study of patients with bipolar I disorder, paving the way for a
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
